Please use this identifier to cite or link to this item:
|Title:||Targeting t-cell adhesion molecules for drug design|
|Authors:||Jois, S.D.S. |
Cell adhesion molecules
|Source:||Jois, S.D.S., Jining, L., Nagarajarao, L.M. (2006-08). Targeting t-cell adhesion molecules for drug design. Current Pharmaceutical Design 12 (22) : 2797-2812. ScholarBank@NUS Repository. https://doi.org/10.2174/138161206777947696|
|Abstract:||Adhesion molecules participate in many stages of immune response; they regulate leukocyte circulation, lymphoid cell homing to tissues and inflammatory sites, migration across endothelial cells and T-cell stimulation. During T-cell immune response, adhesion molecules form a specialized junction between T-cell and the antigen presenting cell. Thus, many researchers have focused their attention on targeting adhesion molecules for developing therapeutic agents. Most of these efforts are intended to develop drugs for autoimmune and inflammatory diseases. Therapeutic agents like efalizumab and alefacept have been approved by the FDA for the treatment of inflammatory autoimmune diseases. This review focuses on some of the basic aspects and importance of adhesion molecules, recent understanding of the structure of adhesion molecules, and the targeted therapeutic agents. © 2006 Bentham Science Publishers Ltd.|
|Source Title:||Current Pharmaceutical Design|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 15, 2018
WEB OF SCIENCETM
checked on Feb 5, 2018
checked on Feb 19, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.